Who makes BIIB023 - low dose IV Dose?

BIIB023 - low dose IV Dose is developed by Biogen.

What development phase is BIIB023 - low dose IV Dose in?

BIIB023 - low dose IV Dose is in Phase 1.

Last reviewed 2026-04-19 · How we verify

BIIB023 - low dose IV Dose

Biogen · Phase 1 active Small molecule

At a glance

Generic name	BIIB023 - low dose IV Dose
Sponsor	Biogen
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BIIB023 - low dose IV Dose CI brief — competitive landscape report
BIIB023 - low dose IV Dose updates RSS · CI watch RSS
Biogen portfolio CI